NextPlat (NXPL) Net Income towards Common Stockholders Growth (3y) (2015 - 2026)
Powered by 
Analysis
NextPlat (NXPL) Net Income towards Common Stockholders Growth (3y) (2015 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.34 Bn | 38.68 Bn | 2.15 Bn | 14.04% |
| 2 | Viatris | 19.39 Bn | 18.50 Bn | 1.46 Bn | -34.81% |
| 3 | Dr Reddys Laboratories | 9.99 Bn | 9.85 Bn | 396.53 Mn | -34.93% |
| 4 | Amneal Pharmaceuticals | 5.57 Bn | 5.53 Bn | 334.51 Mn | 80.10% |
| 5 | Bausch Health Companies | 2.45 Bn | 1.58 Bn | 2.10 Bn | 112.75% |
| 6 | Ani Pharmaceuticals | 1.70 Bn | 1.34 Bn | 165.89 Mn | 61.73% |
| 7 | Alvotech | 1.66 Bn | 1.52 Bn | 2.56 Mn | - |
| 8 | Amphastar Pharmaceuticals | 985.90 Mn | 695.77 Mn | 93.47 Mn | 4.72% |
| 9 | Fennec Pharmaceuticals | 434.07 Mn | 392.82 Mn | 17.15 Mn | 33.27% |
| 10 | NextPlat | 24.77 Mn | 12.93 Mn | 4.69 Mn | 67.87% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 67.87% |
| Mar 31, 2026 | 1.98% |
| Dec 31, 2025 | -89.36% |
| Sep 30, 2025 | 27.41% |
| Jun 30, 2025 | -2.61% |
| Mar 31, 2025 | -31.70% |
| Dec 31, 2024 | 11.94% |
| Sep 30, 2024 | -22.29% |
| Jun 30, 2024 | -53.85% |
| Mar 31, 2024 | -21.80% |
| Dec 31, 2023 | -6.53% |
| Sep 30, 2023 | 72.50% |
| Jun 30, 2023 | -448.93% |
| Mar 31, 2023 | -60.92% |
| Dec 31, 2022 | -35.22% |
| Sep 30, 2022 | -166.00% |
| Jun 30, 2022 | -107.37% |
| Mar 31, 2022 | -53.12% |
| Dec 31, 2021 | -80.58% |
| Sep 30, 2021 | -92.27% |